Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)

Novartis

Status and phase: Completed; Phase 2

Conditions: Gastrointestinal Stromal Tumors

Treatments: Drug: Imatinib Mesylate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00237172

CSTI571B1202

Details and patient eligibility

About

This is a extension study of CSTI571B1201 study

Enrollment: 72 patients

Sex: All

Ages: 20 to 74 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who completed the CSTI571B1201 study

Exclusion criteria

Other protocol-defined inclusion / exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

72 participants in 1 patient group

Imatinib Mesylate

Experimental group

Description:

400 mg once daily

Treatment:

Drug: Imatinib Mesylate